Related resources and publications
VISTA - safety and PK profiling
Nat Commun
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/65829fd6c3d918f937e6169d_img-poster-sensei-2022.jpg)
BRGSF-HIS & hVISTA for immunotherapies
The hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.
hVISTA allows for efficacy assessment of human VISTA-targeting compounds in various fields, such as immuno-oncology, autoimmune diseases and inflammation
hVISTA and mVISTA expression on freshly isolated splenocytes on A) Tregs, B) CD11bHigh, C) conventional CD4 (CD4conv), and D) CD8 T cells. VISTA is not detected on cells from VISTA Knockout homozygous mice.
Mice of indicated genotype were inoculated with MC38 tumor cells s.c. and treated αKLH (control), αmPD-1, αhVISTA or αmPD-1 + αhVISTA (combination). Tumor volume measurement in A) wild-type and B) hVISTA Knockin (KI) homozygous mice at different time points. Results are expressed as mean±SEM. C) Survival of treated hVISTA KI homozygous mice analyzed up to 50 days post MC38 tumor inoculation.
VISTA - safety and PK profiling
Nat Commun
BRGSF-HIS & hVISTA for immunotherapies
The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.
Let us know how we can help
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate